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SUMMARY
Accelerating cures for children with cancer remains an immediate challenge as a result of 
extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms 
evolving between diagnosis and relapsed disease, and limited therapeutic options. To 
systematically prioritize and rationally test novel agents in preclinical murine models, researchers 
within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived 
xenografts (PDXs)—many of which are refractory to current standard-of-care treatments—from 
high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique 
pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our 
understanding of relapsed disease. In addition, we use expression signatures to classify tumors for 
TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for 
pediatric oncology drug development and will guide rational clinical trial design for children with 
cancer.
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In Brief
Rokita et. al provide an extensively annotated genomic dataset of somatic oncogenic regulation 
across 37 distinct pediatric malignancies. The 261 patient-derived xenograft models are available 
to the scientific community, and the genomic annotations will enable rational preclinical agent 
prioritization and acceleration of therapeutic targets for early-phase pediatric oncology clinical 
trials.
INTRODUCTION
An estimated 15,780 children and adolescents (<20 years) are diagnosed with cancer in the 
United States each year, and these diverse entities are the leading cause of disease-related 
deaths in children (American Childhood Cancer Organization, 2014). Despite five-year 
survival rates for pediatric cancers now exceeding 80%, survivors frequently have lifelong 
side effects from cytotoxic therapy, and survival outcomes for children with certain types of 
tumors remain dismal. The relative rarity of pediatric cancers, molecular and mechanistic 
heterogeneity of subtypes within and across histologies, genetic and molecular distinction 
from adult malignancies, tumor evolution in the face of cytotoxic standard therapies, and 
lack of targeted therapeutic agents all pose major challenges to improving outcomes for 
children with cancer. Indeed, there are very few drugs with specific labeled indications for 
pediatric malignancies, and most standard therapies are largely empiric.
Preclinical testing of new therapeutic anti-cancer agents is essential in the field of pediatric 
oncology due to the relative rarity of the condition and the need to prioritize agents for early-
phase clinical trials. Over the past 15 years, the Pediatric Preclinical Testing Consortium 
(PPTC), previously known as the Pediatric Preclinical Testing Program (Houghton et al., 
2002, 2007), has developed over 370 patient-derived xenograft (PDX) models from high-risk 
childhood cancers. In collaboration with pharmaceutical and academic partners, the PPTC 
systematically screens novel therapeutic agents for anti-tumor efficacy in order to help 
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prioritize those that will move to the clinic. Previous studies have characterized subsets of 
pediatric xenograft models, often with limited numbers of specific histologies and/or 
genomic assays (Brabetz et al., 2018; El-Hoss et al., 2016; Stewart et al., 2017; Townsend et 
al., 2016; Whiteford et al., 2007). Here, we present a comprehensive genomic 
characterization of 261 models from 29 unique pediatric cancer malignancies.
RESULTS
Genomic Analysis Workflow and Histological Summary of Pediatric PDX Tumors
Figure 1 depicts the overall workflow of our study, including model histologies, site of 
tumor specimen, phase of therapy, and molecular assays performed. The PDX generation 
methods are described in the STAR Methods. We performed whole-exome sequencing 
(WES) on 240 childhood cancer PDX models, whole-transcriptome sequencing (RNA 
sequencing [RNA-seq]) on 244 models, and SNP microarrays on 252 models (Figures 1 and 
S1; Table S1), and we performed short tandem repeat (STR) profiling on all 261 models 
(Table S2). Of the 261 models profiled, 82 had available references that are also included in 
Table S2.
Figure S1 describes the analysis workflow (see STAR Methods for details). Of the 240 
models on which WES was performed, 69 models were previously sequenced through 
efforts of the PPTP (dbGAP: phs000469.v17.p7), and we harmonized these data. For WES 
(Figure S1C) and RNA-seq (Figure S1D), we performed competitive mapping to a hybrid 
human-mouse reference (hg19-mm10) and used human-specific BAM files as input for 
downstream analyses. We validated this biochemically with qPCR by calculating the ratio of 
human:mouse DNA in a subset of 35 PDX tumors. We found a significant correlation 
between the percent of human reads following WES hybrid mapping and the percent of 
human DNA in the tumor extract (Figure S1B; Pearson correlation R = 0.943, F = 272.5, df 
= 34, p value < 2.2e–16). A mutation annotation format (MAF) file of common germline 
variation was created if a variant was present in more than five normal samples from The 
Cancer Genome Atlas (TCGA) patients (n = 809). The remaining variants, comprising both 
somatic and rare germline alterations, were collated into the “somatic” MAF file. Artifactual 
sequencing variants were removed as described in the STAR Methods. Common germline 
SNP distributions (allele frequency > 0.005 in any one of the three databases: Exome 
Aggregation Consortium, 1,000 genomes, or the NHBLI Exome Sequencing Project) were 
plotted for each model and visually inspected for a negatively skewed distribution to assess 
DNA cross-contamination in WES data. To identify potential misidentification, RNA variant 
calling was performed, and variant allele frequencies were correlated between WES and 
RNA. Models whose variants did not correlate were deemed misidentified and removed 
(STAR Methods). Within this cohort, five pairs of models were derived from tissue at the 
phase of therapy (Table S1). Thus, as additional quality control (QC), we correlated somatic 
mutation allele frequencies between each pair and found a high concordance of mutation 
frequencies (data on Figshare; STAR Methods), confirming the biological reproducibility of 
creating PDX models within a center. Mutation variation is summarized per model in Table 
S3.
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SNP arrays were processed for segmentation, focal copy number, and ethnicity inference 
(STAR Methods; Figures S1A and S2). As reported ethnicities were only available for a 
small proportion of the models, we used SNP array genotypes to infer approximate 
ethnicities using HapMap genotype frequencies. We assigned models to African, East Asian, 
European, and South Asian/Hispanic ethnicities (Figure S2; Table S1). Overall, 71% of 
models are of predicted European descent, 11.5% South Asian/Hispanic, 9.1% African, 
5.5% mixed or unknown ethnicity, and 2.4% East Asian.
Following rigorous assessment for contamination, misidentification, and sample mislabeling, 
26 full models were excluded, and 3 RNA samples were excluded. The remaining 261 
models used herein were shown to be free of detectable levels of DNA contamination (STAR 
Methods).
PDX Models Recapitulate the Mutation and Copy-Number Landscape of Childhood 
Cancers
We highlight hallmark alterations in key pediatric tumor driver genes (Behjati et al., 2017; 
Eleveld et al., 2015; Gröbner et al., 2018; Liu et al., 2017; Ma et al., 2018; Pugh et al., 2013; 
Shern et al., 2014; Zhang et al., 2012) in Figure 2 and demonstrate faithful disease 
recapitulation across PDX models.
Acute Lymphoblastic Leukemias—Figure 2A depicts oncoprints for 90 acute 
lymphoblastic leukemia models.
BCP ALLs—A total of 45%–48% of B cell precursor acute lymphoblastic leukemia (BCP-
ALL) PDX models contain canonical focal deletions of the tumor suppressors on 
chromosome 9p, CDKN2A or CDKN2B (Figures 2A and S4B), the majority of which are 
homozygous. The BCP-ALL models were enriched for alterations in the RAS pathway 
(KRAS mutated in 30%, NRAS mutated in 18%) and the JAK-STAT pathway (JAK2/3 
altered in 15%), and 15% have altered KMT2D. These pathways, along with PI3K/AKT, 
TNFα, and TP53 signaling, were all significantly enriched in gene expression data (Figure 
5B). Finally, we detected fusion transcripts in 78% of BCP-ALL models (25/33), many of 
which contain ETV6 (27%; 88% of these partner with RUNX1), PAX5 (18%), and CRLF2 
(6%) (Table S5).
ETP and T-ALLs—Early T cell precursor-ALL (ETP-ALL) and T cell-ALL (T-ALL) 
models are predominantly characterized by CDKN2A/B focal deletions (72%–76%; Figure 
S4B) and/or a NOTCH1 mutation (68%). Genes within the JAK-STAT pathway are also 
frequently altered with concurrent pathway enrichment (Figure 5B). JAK1 or JAK2 lesions 
were observed in 24% of the models, and 4% of the models contain lesions in STAT5B. We 
detected oncogenic fusion transcripts in nearly half (48%) of these models, many partnering 
with the following genes: TRBC2 (16%), TRBC1 (12%), ABL1 (8%), IGH (8%), LMAN2 
(4%), LMO1 (4%), LMO2 (4%), and ETV6 (4%).
Ph-like and Ph+ ALLs—We confirmed the presence of a BCR-ABL1 fusion in all three 
Ph+-ALL models (ALL-04, ALL-55, and ALL-56). Eight Ph-like ALL models (42%; 10/19) 
contain a canonical CRLF2 fusion; seven partner with P2RY8 and one with IGHM. 
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Additional frequently rearranged genes include JAK2 (55%; 12/22) and PAX5 (23%; 5/22). 
In both Ph+ and Ph-like ALL models, focal deletions of CDKN2A/B (45%, 10/22; Figure 
S4B) are predominant. Frequently altered pathways include Ras and JAK-STAT (Figures 2A 
and 5B).
MLL-ALLs—All mixed lineage leukemia-ALL (MLL-ALL) models contain a canonical 
KMT2A fusion and have relatively silent genomes with minimal copy number alterations 
(Figure S4B). The majority of these models were derived from children <1 year of age 
(Table S1).
Molecular Subtyping and Genomic Landscape of CNS Tumors
Models derived from CNS and extracranial rhabdoid tumors were further molecularly 
classified using pathology reports or genomic features from WES, RNA, and SNP arrays 
(Figure 1; Table S1). Atypical teratoid rhabdoid tumor (ATRT) models represented both 
Sonic hedgehog (SHH; n = 3) and MYC (n = 3) subgroups, with two models unclassified. To 
classify medulloblastoma models, we developed and applied a classifier for RNA-seq data 
(STAR Methods). The 20 medulloblastoma models in this cohort span all broad subtypes: 
SHH (n = 7), WNT (n = 2), group 3 (n = 7), and group 4 (n = 3), and one model without 
RNA-seq remained unclassified. Other CNS embryonal tumors were classified into 
embryonal tumor with multi-layer rosettes (ETMR; n = 3), CNS Ewing with CIC alteration 
(CNS EFT-CIC; n = 2), ependymoblastoma (n = 1), or CNS embryonal not otherwise 
specified (CNS embryonal not otherwise specified [NOS]; n = 1). Astrocytoma models 
comprised pleomorphic xanthroastrocytomas (PXA; n = 2), MYCN subtype (n = 2), 
glioblastomas (IDH-wild-type; n = 5), histone H3-wild-type diffuse intrinsic pontine glioma 
(DIPG; n = 2), and a histone H3-wild-type astrocytic tumor (n = 1). Ependymal tumors were 
classified into supratentorial RELA positive (ST-EPN-RELA; n = 2), supratentorial YAP1 
positive (ST-EPN-YAP; n = 2), posterior fossa type A (PF-EPN-A; n = 1), or posterior fossa 
type B (PF-EPN-B; n = 1), and one remained unclassified.
All ATRT and extracranial rhabdoid models harbor inactivating alterations (focal deletion, 
frameshift deletion, or nonsense mutation) in the hallmark tumor suppressor, SMARCB1, 
and/or SMARCA4. Hedgehog, TNFα, and p53 signaling were enriched in these models 
(Figure 5B). Interestingly, three astrocytic tumors harbored SMARCB1 hemizygous 
deletions, which have not been reported but are present in multiple pediatric high-grade 
glioma cohorts (Mackay et al., 2017: 6.7%, n = 834; Ijaz et al., 2019: 7.5%, n = 93) and may 
warrant further investigation. One astrocytic model, IC-1621GBM, was generated from a 
patient with DNA mismatch repair deficiency syndrome and showed 124 somatic mutations 
per medulloblastoma (MB) (Table S3). We confirmed multiple mutations in mismatch repair 
genes PMS1, MSH2, MSH5, and POLE (non-exonuclease domain mutation). The likely 
oncogenic drivers are the nonsense mutations in PMS1 (Q316*) and MSH2 (G721*), which 
disrupt the DNA mismatch repair protein domain and the MutS domain, respectively (Figure 
S3C). NCH-MN-1 was derived from a patient diagnosed with an anaplastic rhabdoid 
meningioma with the clinical suspicion of an ATRT; however, this model had no evidence of 
an inactivating SMARCB1 alteration. Rather, it harbors a BRAF V600E mutation and focal 
CDKN2A/B deletion, classifying this model as a high-grade glioma, herein denoted as an 
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astrocytoma. Not surprisingly, astrocytoma and glioblastoma models had similar pathway 
enrichment: estrogen response, hedgehog signaling, protein secretion, TNFα, and p53 
pathway (Figure 5B).
IC-2664PNET was derived from a patient diagnosed with a primitive neuroectodermal 
tumor (PNET) but was further molecularly classified as a MYCN-subtype high-grade 
glioma. IC-2664PNET has a focal amplification of MYCN and a hemizygous SMARCB1 
deletion, but it retains mRNA expression of SMARCB1. ICb-S1129MB, ICb-1343ENB, and 
IBs-2373PNET were classified as ETMRs due to an amplification of C19MC, an 
overexpression of LIN28A, and/or TTYH1 fusions. ICb-9850PNET and IC-22909PNET-
rIII, a diagnosis-relapse pair, were genetically classified as CNS EFT-CIC, as the diagnostic 
tumor contains a CIC-DUX4 fusion. The two DIPG models were profiled with RNA-seq and 
SNP arrays and thus are not shown in the oncoprint. We confirmed both IBs-P1215DIPG 
and IBs-W0128DIPG have high expressions of H3F3A and H3F3B (FPKM > 50), genes 
encoding the histone H3.3 variant, and lack expressions of HIST1H3B or HIST1H3C, genes 
encoding the histone H3.1 variant. While we did not detect H3.1 or H3.3 histone mutations 
in these models, RNA variant calling revealed IBs-W0128DIPG contained predicted 
damaging (PolyPhen) missense mutations in NRAS (p.G13R, 0.41), CIC (p.C102Y, 0.44), 
and KMT2C (p.C988F, 0.45). We did not detect any hallmark damaging mutations in IBs-
P1215DIPG.
Extracranial Solid Tumors
Neuroblastomas—Amplification of the MYCN oncogene was the most frequent 
alteration observed across all models (66%) and, as expected, was largely mutually exclusive 
of 11q deletion. Gene set enrichment analysis (GSEA) confirmed the enrichment of MYC 
targets in these models (Figure 5B). A majority (77%) of models had 1p deletion and 17q 
gain (97%; collapsed profiles are shown in Figure S4A). Consistent with previous reports 
(Pugh et al., 2013), we find ALK to be the most frequently mutated gene (37% of all models 
contain hotspot mutations) with additional, less frequent alterations in hallmark genes such 
as TP53 (11%), PTPN11 (9%), NF1 (9%), BRAF (3%), CIC (3%), and KRAS (3%). The 
nonsense and frameshift deletions in NF1 correspond with ablated expressions in COG-
N-590x and NB-1771, respectively, but NB-1643 retains expression.
Osteosarcomas—The hallmark of osteosarcomas is TP53 inactivation, and using a 
classifier trained on RNA expression data from TCGA, we found all osteosarcoma models 
with available RNA-seq data (n = 32) were predicted to have non-functional TP53 
(described below). Thus, as expected, TP53 was the most commonly altered gene (82%) in 
osteosarcoma PDX models (Figure 2C), which also demonstrate global copy number 
changes, consistent with the high prevalence of complex genomic rearrangements found in 
this tumor type (Figure S4).
Ewing Sarcomas—The canonical EWSR1-FLI1 fusion was found in all Ewing sarcoma 
models profiled with RNA-seq (NCH-EWS-1 was not profiled), and CHLA-258 contained 
an additional FLI1 fusion partner: RP11-9L18.2 (Table S5; Figure 2C). TP53 mutations are 
present in seven cases (70%), with six showing allele frequencies at or near 1.0 due to copy-
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neutral loss of heterozygosity (cnLOH, ES-6, EW-8, and SK-NEP-1) or loss of 
heterozygosity (LOH) from a chromosomal arm deletion (EW-5, ES-8, and TC-71). 
Homozygous CDKN2A/B loss (60%) was mutually exclusive to STAG2 mutations (20%), 
as expected (Tirode et al., 2014). We observe canonical (Tirode et al., 2014) broad gain of 
whole chromosomes 8 and 12, as well as focal 1q gain and 16q loss, in Ewing sarcomas 
(Figure S4A).
Wilms Tumors—The mutational and copy number landscapes of Wilms tumor (n = 13) 
PDX models are depicted in Figures 2C and S4A. The WT1 gene located at 11p13 was 
mutated in one PDX model (NCH–WT–6–S13–1506), but we observed hemizygous 
deletions of WT1 in 61% of Wilms models, many of which had LOHs of the entire 11p13 
region. The 11p15.5 region, which contains imprint control regions (ICRs) 1 and 2, often 
undergoes loss of imprinting (LOI) either due to maternal DNA methylation or maternal 
LOH/paternal uniparental disomy (pUPD) in a Wilms tumor. The 11p15.5 region harbored 
LOHs in 69% (9/13) of Wilms tumors, consistent with previous reports (Scott et al., 2012). 
Two models (15%) harbored hemizygous deletions of AMER1 (formerly known as WTX 
and/or FAM123B). KT-9 is the only model annotated as coming from a patient with bilateral 
disease, and although it does not harbor a WT1 mutation, interestingly, it has two hits in 
TP53: a TP53-FXR2 fusion and a partial homozygous deletion. The Wilms models (15%; 
KT-6 and NCH-WT-6-S13-1506) with CTNNB1 mutations were mutually exclusive to 
WTX alterations, consistent with previous reports (Scott et al., 2012). Gains of the 1q arm, 
1p LOH, and 16q LOH–adverse prognostic biomarkers for Wilms tumors (Pan et al., 2017; 
Segers et al., 2013; Spreafico et al., 2013)–were observed in 31% (4/13), 8% (1/13), and 
23% (3/13) of models, respectively (Figure S4).
Rhabdomyosarcomas—All Fusion+ rhabdomyosarcoma (RMS) models harbored a 
hallmark PAX3-FOXO1 fusion (Figure 2C; Table S1), and the median patient age of Fusion
+ RMS patients (16 years) was higher than that of Fusion− RMS patients (5 years) (Table 
S3). As expected, we also observed focal amplifications of MYCN and CDK4. Interestingly, 
the amplification of CDK4 was not retained in Rh-30R (relapse tumor paired with Rh-30; 
SNPs and STRs confirm identity). Ras pathway mutations (NRAS, HRAS, KRAS, and NF1) 
are typically observed in one-third of Fusion− RMS cases and here, Ras mutations were 
observed in 3/6 models (Rh-12 with NF1 T2335fs, NCH–ERMS–1–NCH–RMS–1 with 
NRAS Q61K mutation, and Rh-36 with HRAS Q61K). Of note, all models except for 
IRS-68 overexpress the common rhabdomyosarcoma biomarker, MYOD1.
Rare Histologies—Seven PDX models were derived from rare tumor types and are 
depicted in Figure 2C. Three models (43%) contained alterations in TP53; of note, an in-
frame hemizygous deletion of TP53 evolved at the relapse in NCH-CA-2 (not present in 
diagnostic model, NCH-CA-1). The canonical ASPSCR1-TFE3 fusion was detected in both 
alveolar soft part sarcoma (ASPS) models. NCH-CA-1 and NCH-CA-2 harbored deleterious 
SMARCA4 mutations, and NCH-CA-3 harbored a deleterious NF1 nonsense mutation; each 
had a concurrent loss of mRNA expression and, as such, these may be potential drivers of 
oncogenesis in these tumors. NCH-HEP1 contained a likely oncogenic WNT pathway 
mutation (CTNNB1 p.D32G).
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Breakpoint Density
We calculated the total number of breakpoints per sample and breakpoint density within 
chromosomes, the latter as a surrogate measure of putative chromothripsis events (STAR 
Methods). Consistent with pediatric cancer genomics literature, we observed very few 
breakpoints per sample in hematologic malignancies, compared to those in solid tumors 
(median = 3 breakpoints per sample in CNS embryonal NOS to median = 154.5 breakpoints 
per sample in osteosarcoma; Figure S4C; Table S3). We found 25% (64/252) of models 
profiled have a high breakpoint density (HBD) across one or more chromosomes (Figure 
S4D; Table S3), consistent with a recent pan-cancer chromothripsis report (Cortes-Ciriano et 
al., 2018). Specifically, 97% (33/34) of osteosarcomas had HBDs; 30% (10/33) of these 
contained HBDs on four or fewer chromosomes indicative of localized chromothripsis 
events, while the remaining 70% (23/33) contained HBDs on five or more chromosomes, 
supporting the globally rearranged genomes prevalent in this tumor type (Lorenz et al., 
2016). In neuroblastoma samples, 17% of models contained HBDs on chromosomes 2, 5, 
16, 17, and 19. Chromothripsis events on chromosomes 2, 5, and 17 in neuroblastoma 
tumors have been previously reported to be associated with MYCN amplification, TERT 
rearrangements, and 17q gain, respectively (Molenaar et al., 2012; Boeva et al., 2013). 
Recurrent loci with HBDs in medulloblastoma were chromosomes 2, 8, 14, and 17, 
consistent with recent reports (Rausch et al., 2012). In summary, PDX models faithfully 
recapitulate important prognostic copy number alterations of pediatric tumors.
Mutational Landscape of Models Derived from Tumors at Relapse
The majority of the PDX models were established at diagnosis (63%), but 6% were derived 
from surgical resection specimens after neoadjuvant therapy, 27% were from a relapsed 
specimen (14% of those were neuroblastomas from a large volume blood draw obtained 
immediately after death from disease progression), and 4% did not have the phase of therapy 
annotated. In addition, 12 pediatric cancer patients had either two or three models created 
across the spectrum of their therapy (Table S1). Here, we compare mutation frequencies and 
tumor mutation burdens (TMBs) for histologies with paired diagnosis-relapse cohorts with 
group N ≥ 6: BCP-ALL (Ndiagnosis = 19/nrelapse = 14), T-ALL (ndiagnosis = 11/nrelapse = 8), 
osteosarcoma (ndiagnosis = 25/nrelapse = 6), and neuroblastoma (ndiagnosis = 12/nrelapse = 23). 
Across all four histologies, there is an increased frequency of key hallmark gene alterations 
in relapsed disease, as indicated by the oncoprint frequencies (Figure 3A). Using somatic 
missense and nonsense mutations, we calculated the TMB for each PDX model (STAR 
Methods). The median TMB across all models was 2.66 somatic mutations per megabase 
(Mut/Mb; Figure S3B; Table S3). The TMBs across this cohort of PDX models are likely 
higher than those in previous reports for two main reasons. First, 37% of the PDX models 
were derived from a patient tumor at a phase of therapy other than diagnosis, and it is now 
known that tumors acquire significantly more somatic mutations post-therapy and following 
a relapse (Eleveld et al., 2015; Ma et al., 2015; Padovan-Merhar et al., 2016; Schleiermacher 
et al., 2014; Schramm et al., 2015). Second, without paired normal samples, rare germline 
and private variants could not be reliably removed from the “somatic” MAF. Thus, the TMB 
reported here is likely inflated, but the trends across histologies and phase of therapy should 
accurately reflect TMBs determined with a paired germline sample. In fact, we observe an 
overall significantly higher TMB in PDX models derived from relapse tissue (3.08 Mut/Mb) 
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compared to those derived at diagnosis (2.57 Mut/Mb, Wilcoxon p = 2.2e–5; Figure 3B). 
When compared to diagnostic tumors within a histology, the TMB was higher at relapse in 
BCP-ALL (Wilcoxon p = 0.054) and significantly higher at relapse in neuroblastoma 
(Wilcoxon p = 0.016) and T-ALL (Wilcoxon p = 0.0081), but it was not different between 
the diagnosis and relapse for osteosarcoma (Wilcoxon p = 0.42). Finally, we compared 
TMBs between paired diagnosis-relapse models and found a significantly higher TMB in 
models derived from relapse tumors (Figure 3B; median of 98.0 versus 27.5 mutations; 
Wilcoxon p = 0.0083). This PDX cohort recapitulates relapsed disease and provides a model 
for further studying tumor progression and therapeutic resistance.
Expression Signatures Classify Pediatric PDX Models for TP53 and NF1 Inactivation
A recent study used TCGA data to classify tumors for TP53 inactivation status and found 
that alterations in multiple genes phenocopy TP53 inactivation, indicating that TP53 
mutation status alone is not necessary to infer the inactivation of the pathway (Knijnenburg 
et al., 2018). We applied a machine learning algorithm to infer TP53 inactivation, NF1 
inactivation, and Ras pathway activation using PDX tumor transcriptomes. These classifiers 
were previously trained using gene expression data from TCGA PanCanAtlas (STAR 
Methods) (Knijnenburg et al., 2018; Way et al., 2017, 2018). The TP53 (area under the 
receiver operator characteristic [AUROC] = 0.89) and NF1 (AUROC = 0.77) classifiers are 
both accurate compared to a shuffled gene expression baseline, but performance of the Ras 
classifier (AUROC = 0.55) was relatively poor (Figure 4A), which may be attributed to 
differences in Ras pathway signatures in pediatric compared to adult tumors. Classifier 
scores >0.5 predict the inactivation of TP53 or NF1 (Table S5), and TP53 scores are 
significantly higher (Wilcoxon p < 2.2e–16) in models with a TP53 alteration (mean score = 
0.790) compared to those without alterations (mean score = 0.419) (Figure 4B). Many 
models annotated as wild-type TP53 have high TP53 inactivation scores (Figure 4B). We 
found models with alterations in genes such as MDM2 and RB1 also have high TP53 
inactivation scores. These alterations may phenocopy TP53 alterations (Figure 4C; genes 
chosen as primary or secondary interactors of TP53 defined by the TP53 KEGG signaling 
pathway). In Figure 4D, we plot alterations for each gene by variant classification. Notably, 
all types of alterations within TP53 were associated with high classifier scores, while the 
scores for other genes varied by type of alteration.
As TP53 inactivation is a hallmark of osteosarcoma, we focused on these models as a proof 
of concept. The classifier predicted that all models profiled with RNA-seq except OS-55-
SBX had TP53 pathway inactivation. Many had a genetic alteration in a TP53 pathway gene 
as supporting evidence (Figure 4E; Table S4). However, the mechanisms of TP53 
inactivation in OS-34-SJ, OS-43-TPMX, and OS-51-CHLX are still unknown and may 
require whole-genome sequencing to detect. To ensure osteosarcoma models were not 
driving the observed association with TP53 scores, we removed the osteosarcoma models 
and reanalyzed the data. We found a significantly higher TP53 classifier score (Wilcoxon p 
= 1.0e–11) in models with alterations in TP53 pathway genes (Figures S5A and S5B). We 
then evaluated which types of variants were associated with high TP53 classification scores 
and observed that models containing fusions had highest classifier scores compared to wild 
types, followed by models with single nucleotide variants (SNVs) and copy number variants 
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(CNVs). (Figure S5C; Kruskal-Wallis p = 9.8e–11). These are broken down by gene in 
Figure S5D. Outside of osteosarcomas, only one model contained a fusion in the TP53 
pathway: Wilms model KT-9 contained a TP53-FXR2 fusion. We found the overall copy 
number burden (number of breakpoints calculated from SNP array data; STAR Methods), 
but not the TMB or shuffle score, correlates significantly with the TP53 classifier score 
(Figure 4E; R = 0.51, p = 1.8e–17), supporting recent published observations (Knijnenburg 
et al., 2018). Genetic alterations rendering TP53 inactive may contribute to copy number 
instability in these models. The use of gene expression classifiers can guide preclinical 
studies: for example, therapeutically targeting the TP53 pathway in tumors with high TP53 
inactivation scores rather than those with altered TP53.
Expression Profiles of PDX Models Cluster by Tissue of Origin and Contain 
Driver Fusions—We used the UCSC TumorMap (Newton et al., 2017) to visualize 
clusters of expression profiles across PDX histologies (Figure 5A). We observed a clear 
separation among unrelated histologies and an overlapping clustering among related 
histologies. For example, T-ALL and ETP-ALL cluster together as expected, but distinctly 
from other ALL histologies. The leukemias clustered by subtype and distinctly from solid 
tumors. Ewing sarcoma, neuroblastoma, Wilms, and medulloblastoma form distinct clusters. 
Osteosarcomas cluster with two ASPS models. Fusion+ and Fusion-RMS cluster near each 
other but distinctly. Brain tumor histologies cluster near each other with the exception of 
ATRTs, some of which cluster with extracranial rhabdoid tumors near sarcoma samples. We 
identified histology-specific expression differences using a Bayesian hierarchical model 
(Gelman, 2006), grouped related histologies under the same prior distribution, ranked gene 
expression differences for each histology, and performed GSEA. This demonstrated tissue-
specific enrichment within each histology, using GSEA and the Tissue-Specific Gene 
Database in Cancer (TissGDB; Kim et al., 2018a) and Tissue-Specific Gene Expression and 
Regulation Database (TiGER; Liu et al., 2008) gene sets (Figure S5F). To investigate 
pathway enrichment within histologies, we ran GSEA using the MSigDB curated (C2) gene 
sets and plotted the normalized enrichment scores (NESs) for the Hallmark pathway gene 
sets in Figure 5B.
Next, we created a high-confidence fusion annotation pipeline (Figure S1; STAR Methods) 
using four algorithms: defuse, FusionCatcher, STARFusion, and SOAPFuse. A total of 
50,796 unique fusions were called, and we defined 925 unique high-confidence fusions and 
92 unique known oncogenic driver fusions defined by cytogenetics and literature (Figure 5C; 
Table S5). Fusions were annotated for their frame and for whether a gene partner is a known 
oncogene, kinase, or transcription factor to identify oncogenic potential and functional 
relevance. We found that PPTC PDX models largely maintain known oncogenic driver 
fusions specific to their histologies: all alveolar rhabdomyosarcoma models harbored PAX3-
FOXO1 fusions, all Ewing sarcoma samples with RNA-seq data showed EWSR1-FLI1 
fusions, all Ph+ ALL tumors contained BCR-ABL1 fusions, and KMT2A (MLL) fusions 
were detected in all MLL-ALL models (Table S5). Osteosarcomas harbored TP53 fusions, 
and breakpoints reside within intron one of the TP53 gene, a mechanism of TP53 
inactivation previously reported in osteosarcoma (Ribi et al., 2015). In five diagnosis-relapse 
pairs, we detected four fusions in the diagnostic PDX (PAX5-RP11-465M18.1, IGH-MYC, 
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CIC-DUX4, and TP53-TNR) that were undetected in their paired relapse model, suggesting 
these specific gene fusions may have been acquired after an alternative initiating event that 
was retained.
DISCUSSION
Here, we used whole-exome, whole-transcriptome, SNP genotyping arrays, and STR 
profiling to characterize 261 pediatric PDX models across 37 unique molecular subtypes. 
We used a competitive mapping approach to remove mouse reads from DNA or RNA-seq 
data and demonstrated high concordance between these pipelines and the orthogonal 
measurement of human:mouse DNA ratios. We showed a faithful recapitulation of primary 
and relapsed disease within tumor of origin type through analysis of somatic mutations, 
copy number alterations, RNA expression, gene fusions, and oncogenic pathways. It is clear 
that the models here are biased toward the most highly aggressive pediatric cancers, which is 
reflective of the typical pediatric phase 1 patient populations.
The data presented herein have immediate applications to the prioritization of experimental 
agents for testing in pediatric preclinical models, leading to eventual clinical testing. For 
example, there are reports identifying specific genomic alterations as predicting sensitivity 
to ATR inhibitors, including ATM loss, ARID1A mutation, defective homologous 
recombination, and ATRX mutation associated with alternative lengthening of telomeres 
(ALTs) (Lecona and Fernandez-Capetillo, 2018). Querying the PPTC data at PedcBioPortal 
can quickly identify models with these characteristics, and the models can then be used to 
test whether in vivo responsiveness to ATR inhibitors is predicted by one or more of the 
molecular characteristics. Similarly, PPTC RNA-seq data can be used to identify models that 
show elevated gene expression for the targets of immunotherapeutics such as antibody-drug 
conjugates and T-cell engagers. As examples, in the PPTC dataset, GPC2 and ALK are 
dramatically overexpressed neuroblastoma models, as previously published (Bosse et al., 
2017; Sano et al., 2019), but also in multiple subsets of additional pediatric cancer 
histotypes, allowing for a basket trial design for preclinical testing. The PPTC RNA-seq 
dataset was also used to identify T-ALL as a target histology for an agent activated by the 
aldo-keto reductase AKR1C3 (R.B. Lock et al., 2018, Mol. Cancer Ther., abstract) and to 
identify ASPS xenografts as intrinsically overexpressing CD274 (PD-L1), making ASPS a 
target histology for the evaluation of checkpoint inhibition (C.G. O’Sullivan et al., 2018, 
Connective Tissue Oncology Society Annual Meeting, conference).
Further, we performed machine learning to classify tumors into TP53 and NF1 active or 
inactive, and we suggest that these scores might be future biomarkers for drug response. 
These classifiers have been used to identify tumors that may respond to novel agents, 
including those that target tumors driven by NF1 loss (Way et al., 2017). Although these 
machine learning algorithms are not ready for the clinic, the next logical step is to use PDX 
models to test the predictive nature of classifiers so that in the future, interdisciplinary teams 
can identify tumors driven by TP53 and/or NF1 loss, evaluate, and compare multiple 
therapies in real time.
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Our study also highlights additional opportunities for pan-pediatric genomic 
characterization. We did not have available models for acute myelogenous leukemia, 
juvenile myelomonocytic leukemia, lymphomas, retinoblastoma, melanoma, thyroid 
malignancies, or histone mutant midline gliomas. Additionally, although we covered 37 
molecular subtypes, many of the rare tumors had low numbers of models and could benefit 
from the creation and sequencing of additional PDXs, and we seek to generate these data 
and/or hope to merge our data with future pediatric cancer PDX sequencing projects. 
Finally, WES likely missed several pathogenic lesions, and DNA methylation profiling is 
particularly relevant for pediatric brain tumors. Future studies, perhaps in collaboration with 
ongoing similar efforts by international colleagues, could address these gaps.
We performed this project to provide a resource to the pediatric cancer research community. 
To date, the pediatric cancer genomic literature largely focuses on diagnostic samples, and 
this study includes a large number of PDXs derived during or after intensive 
chemoradiotherapy. Thus, the frequency of many genomic alterations is higher in these 
models compared to the literature. By having a large number of PDXs obtained from 
samples at relapse or at autopsy, we can provide models that more closely recapitulate the 
patients being enrolled in early-phase clinical trials after extensive chemoradiotherapy. All 
models and data are freely available for the cancer research community, as described in the 
STAR Methods.
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to, and will 
be fulfilled by, the Lead Contact, John M. Maris (maris@email.chop.edu). All PDX models 
are available through the Pediatric Preclinical Testing Consortium with a completed Material 
Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient-Derived Xenograft Generation and Harvesting—Patient-derived xenograft 
models from the Pediatric Preclinical Testing Program (PPTP) were generated as described 
(Houghton et al., 2002, 2007; Whiteford et al., 2007). Briefly, for solid tumors, C.B-Igh-1b/
IcrTac-Prkdcscid (Taconic Farms, Germantown NY), were subcutaneously flank-engrafted 
into male or female mice (Table S1) and passaged once tumors reached 200 mm3. For CNS 
tumors, patient tumors were stereotactically-transplanted into anesthetized (50 mg/kg 
sodium pentobarbital) RAG2, NOD.129S7(B6)-Rag1tm1Mom/J, or RAG1tm1Mom/J mouse 
brains in the diagnosis-specific orthotopic locations noted in Table S1 (Yu et al., 2010). PDX 
tumor cells (1 × 105) were suspended in 2 ul of culture media and slowly injected through a 
burr hole using a 10 ul, 26 gauge syringe into the brain region of interest. Once moribund, or 
displaying neurological deficit symptoms, mice were euthanized and whole murine brains 
containing visible tumors were aseptically removed and transferred to the tissue culture 
laboratory. Tumors were microscopically dissected from surrounding brain tissue, 
mechanically dissociated into cell suspensions, and filtered. Single tumor cells were 
subsequently injected into the brains of SCID mice as described above. Sub-transplantation 
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process was repeated to complete a total of five tumor passages. All animal experiments 
were conducted according to an Institutional Animal Care and Use Committee-approved 
protocol. All leukemia animal experimentation was approved by the Animal Care and Ethics 
Committee, UNSW Sydney (Sydney, Australia). Experiments used continuous PDXs 
established previously in 20-25 g female non-obese diabetic/severe combined immuno-
deficient (NOD.CB17-Prkdcscid/SzJ, NOD/SCID) or NOD/SCID/interleukin-2 receptor γ-
negative (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NSG) mice. Leukemia cells were inoculated 
intravenously into 6-8 week-old NOD/SCID or NSG mice (Australian BioResources, Moss 
Vale, NSW, Australia) and leukemia burden monitored via enumeration of human CD45+ 
(%huCD45+) cells versus total CD45+ leukocytes (human plus mouse) in the peripheral 
blood (PB) and tissues, as reported (Liem et al., 2004; Lock et al., 2002). The continuation 
of xenograft lines was accomplished through harvesting human leukemia cells from the 
spleens of the engrafted mice. Harvesting required more than 3 × 108 leukemia cells per 
spleen, at 85% purity. Additional details per model including sex, age, and mass are included 
in Table S1.
METHOD DETAILS
Nucleic Acid Extractions and Quality Control—PDX samples were submitted from 
Children’s Cancer Institute, Children’s Hospital of Philadelphia, Greehey Children’s Cancer 
Research Institute, and Montefiore Medical Center to the Nationwide Children’s Hospital 
Biospecimen Core Resource at −190°C using an MVE cryoshipper. Cytospins and H&E 
frozen sections were prepared from leukemia and solid tissue PDX specimens, respectively. 
Slides were assessed by board-certified pathologists to determine blast percentage in 
leukemia PDX samples, and percent tumor nuclei and necrosis of the solid PDX samples. 
DNA and RNA were co-extracted from the PDXs using a modification of the DNA/RNA 
AllPrep kit (QIAGEN). The flow-through from the QIAGEN DNA column was processed 
using a mirVana miRNA Isolation Kit (Ambion). DNA was quantified by PicoGreen assay 
and RNA samples were quantified by measuring Abs260 with a UV spectrophotometer. DNA 
specimens were resolved by 1% agarose gel electrophoresis to confirm high molecular 
weight fragments. RNA was analyzed via the RNA6000 Nano assay (Agilent) for 
determination of an RNA Integrity Number (RIN). The PPTC study committee reviewed the 
pathology and molecular QC data and selected DNA and RNA aliquots for sequencing.
Short Tandem Repeat (STR) Profiling—Each tumor DNA sample was subjected to 
STR profiling performed by Guardian Forensic Sciences. DNA samples were quantified 
using QIAGEN Investigator Quantiplex Kit (Cat# 387018) on a QIAGEN RotorGene Q 
instrument. The GenePrint24 System for STR profiling (Promega, Cat#B1870) was used to 
amplify 0.05 ng of template DNA in a 12.5 μL volume using the following conditions: 96°C 
for 1 minute, 27 cycles of {94°C for 10 s, 59°C for 1 minute, 72°C for 30 s}, 60°C for 10 
minutes using the RotorGene Q instrument. Samples were injected into the Applied 
Biosystems ABI 310 Genetic Analyzer and profiles were interpreted by forensic biologists. 
Only those samples deemed not misidentified and free of contamination were used in this 
study.
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Biochemical Measurement of Human DNA Content in PDX Tumors—To 
determine the composition of human and mouse DNA within PDX tumors, PDX DNA 
samples were amplified using modified version of the published pTGER2 (prostaglandin E 
receptor 2) qPCR assay (Alcoser et al., 2011). Depending upon sample availability, 2-20 ng 
of PDX tumor DNA were added to 500 nM each human- and mouse-specific forward 
primers, reverse primers, probes (sequences in resource document) and 1X IDT PrimeTime 
Gene Expression 2X Mastermix (Integrated DNA Technologies) in a total of 20 uL. 
Reactions were thermalcycled at 95°Cfor 8 min and 42 cycles of {95°Cfor 15 s, 64°C for 1 
min}. Five-point standard curves were performed using a mixture of CHLA-90 and COG-
N-603 neuroblastoma cell lines as human-specific template and pooled liver/spleen/muscle 
DNA from a naive NU/NU mouse as the mouse-specific template to confirm each primer 
efficiency was between 90%–110%. The DNA equivalent of one diploid copy of either 
mouse or human template was run as a reference template. Three technical replicates were 
performed for each standard and sample. Average CT values of the reference DNA samples 
were used as “ground truth” CT values for one DNA copy. To estimate relative copy number, 
2−ΔCT values were calculated for each unknown for each species: 2−ΔCT = 
2−(CT of Unknown−CT of Refererence). To estimate percent human content, the following equation 
was used: %Human content = (Relative human genome copies × 100/Relative mouse 
genome copies).
Additional Quality Control for Cross-Contamination and Mis-Identification—
Common germline SNP distributions (allele frequency > 0.005 in any one of the three 
databases: Exome Aggregation Consortium, 1000 genomes, or the NHBLI Exome 
Sequencing Project) were plotted for each model and visually inspected for a negatively 
skewed distribution to assess DNA cross-contamination in WES data. To identify potential 
mis-identification, RNA variant calling was performed and variant allele frequencies 
correlated between WES and RNA. Models whose variants did not correlate were deemed 
mis-identified and removed (STAR Methods). For remaining models, NGScheckmate was 
performed between WES and RNA data. All models except for ICb-2002EPN had 
correlation values of ≥ 0.61 at depths of ≥ 10, deeming these models matched as 
recommended by Lee et al. (2017). ICb-2002EPN had a borderline correlation of 0.6025 at a 
depth of 14.51, but deemed matched from WES-RNA mutation correlations. Within this 
cohort, five pairs of models were derived from tissue at phase of therapy (Table S1). Thus, as 
additional QC, we correlated somatic mutation allele frequencies between each pair and 
found high concordance of mutation frequencies (data on Figshare, STAR Methods), 
confirming biological reproducibility of creating PDX models within a center. Mutation 
variation is summarized per model in Table S3.
Whole Exome Sequencing—Illumina paired-end pre-capture libraries were constructed 
from PDX DNA samples according to the manufacturer’s protocol (Illumina 
Multiplexing_SamplePrep_Guide_1005361_D) modified as described in the BCM-HGSC 
Illumina Barcoded Paired-End Capture Library Preparation protocol. The complete protocol 
including oligonucleotide sequences used as adaptors and blockers are accessible from the 
HGSC website https://www.hgsc.bcm.edu/sites/default/files/documents/Protocol-
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Illumina_Whole_Exome_Sequencing_Library_Preparation-KAPA_Version_BCM-
HGSC_RD_03-20-2014.pdf. The DNA sequence production is briefly described below.
Library Preparation: 500 ng (or 250 ng if sample quantity was limiting) of DNA in 50ul 
volume were sheared into fragments to an average size of 200-300 bp in a Covaris plate with 
E220 system (Covaris, Inc. Woburn, MA) followed by end-repair, A-tailing and ligation of 
the Illumina multiplexing PE adaptors. Pre-capture Ligation Mediated-PCR (LM-PCR) was 
performed for 6-8 cycles using the Library Amplification Readymix containing KAPA HiFi 
DNA Polymerase (Kapa Biosystems, Inc.). Universal primer LM-PCR Primer 1.0 and LM-
PCR Primer 2.0 were used to amplify the ligated products. Reaction products were purified 
using 1.8X Agencourt AMPure XP beads (Beckman Coulter) after each enzymatic reaction. 
Following the final 1.2X Agencourt XP beads purification, quantification and size 
distribution of the pre-capture LM-PCR product was determined using Fragment Analyzer 
capillary electrophoresis system (Advanced Analytical Technologies, Inc.).
Capture Enrichment: Four pre-capture libraries were pooled together (~750 ng/sample, 3 
ug/pool) and then hybridized in solution to the HGSC VCRome 2.1 design1 (Bainbridge et 
al., 2011) according to the manufacturer’s protocol NimbleGen SeqCap EZ Exome Library 
SR User’s Guide (Version 2.2) with minor revisions. Probes for exome coverage across > 
3,500 clinically relevant genes that are previously < 20X (~2.72Mb) is supplemented into 
the VCRome 2.1 probe. Human COT1 DNA was added into the hybridization to block 
repetitive genomic sequences. Blocking oligonucleotides from Sigma (individually sequence 
specifically synthesized) or xGen Universal Blocking oligonucleotides (Integrated DNA 
Technologies) were added into the hybridization to block the adaptor sequences. 
Hybridization was carried out at 560C for ~16h. Post-capture LM-PCR amplification was 
performed using the Library Amplification Readymix containing KAPA HiFi DNA 
Polymerase (Kapa Biosystems, Inc.) with 12 cycles of amplification. After the final AMPure 
XP bead purification, quantity and size of the capture library was analyzed using the Agilent 
Bioanalyzer 2100 DNA Chip 7500. The efficiency of the capture was evaluated by 
performing a qPCR-based quality check on the four standard NimbleGen internal controls. 
Successful enrichment of the capture libraries was estimated to range from a 6 to 9 of ΔCT 
value over the non-enriched samples.
DNA Sequencing: Library templates were prepared for sequencing using Illumina’s cBot 
cluster generation system with TruSeq PE Cluster Generation Kits (Illumina) according to 
the manufacturer’s protocol. Briefly, these libraries were denatured with sodium hydroxide 
and diluted to 6-9 pM in hybridization buffer in order to achieve a load density of ~800K 
clusters/mm2. Each library pool was loaded in a single lane of a HiSeq flow cell, and each 
lane was spiked with 1% phiX control library for run quality control. The sample libraries 
then underwent bridge amplification to form clonal clusters, followed by hybridization with 
the sequencing primer. Sequencing runs were performed in paired-end mode using the 
Illumina HiSeq 2000 platform. Using the TruSeq SBS Kits (Illumina), sequencing-by-
synthesis reactions were extended for 101 cycles from each end, with an additional 7 cycles 
for the index read. With sequencing yields averaging 12.1 Gb per sample, samples achieved 
an average of 97.64% of the targeted exome bases covered to a depth of 20X or greater.
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Primary Data Analysis: Initial sequence analysis was performed using the HGSC Mercury 
analysis pipeline (Challis et al., 2012; Reid et al., 2014). In summary, the. bcl files produced 
on-instrument were first transferred into the HGSC analysis infrastructure by the HiSeq 
Real-time Analysis module. Mercury then ran the vendor’s primary analysis software 
(CASAVA) to de-multiplex pooled samples and generate sequence reads and base-call 
confidence values (qualities), followed by the mapping of reads to the GRCh37 Human 
reference genome (https://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/) 
using the Burrows-Wheeler aligner (Li and Durbin, 2010). The resulting BAM (binary 
alignment/map) file underwent quality recalibration using GATK, and where necessary the 
merging of separate sequence-event BAMs into a single sample-level BAM. BAM sorting, 
duplicate read marking, and realignment to improve in/del discovery all occur at this step. 
Next, Atlas-SNP and Atlas-indel from the Atlas2 suite (Shen et al., 2010) were used to call 
variants and produce a variant call file (VCF). Finally, annotation data was added to the VCF 
using a suite of annotation tools “Cassandra” (https://www.hgsc.bcm.edu/software/
cassandra) that brings together frequency, function, and other relevant information using 
AnnoVar with UCSC and RefSeq gene models, as well as a host of other internal and 
external data resources.
SNP Array Assay—In brief, 200 ng of genomic DNA were denatured with NaOH, 
followed by isothermal whole genome amplification at 37°C for 20-24 hours. The amplified 
DNA was enzymatically fragmented and hybridized to the BeadChip for 16-24 hours at 
48°C (24 samples were processed in parallel for each BeadChip). After a series of washing 
steps to remove unhybridized and non-specifically hybridized DNA fragments, allele-
specific single-base extension reactions were performed to incorporate labeled nucleotides 
into the bead-bound primers. A multi-layer staining process was conducted to amplify 
signals from the labeled extended primers, and then the coated beads were imaged with the 
Illumina iScan system.
Chip types used were humanomniexpress-24-v1-1-a.bpm and 
InfiniumOmniExpress-24v1-2_A1.bpm.
Whole Transcriptome Sequencing—Whole-transcriptome RNA sequencing (RNA-
seq) was performed using total RNA extracted as described above. Strand-specific, poly-A+ 
RNA-seq libraries for sequencing on the Illumina platform were prepared using 
manufacturer guidelines with minor modifications described herein (Peters et al., 2015; 
Wang et al., 2015). RNA Integrity was confirmed (RIN > 7.0) on a Bioanalyzer (Agilent). 
Briefly, poly-A+ mRNA was extracted from 1 μg total RNA using Oligo(dT)25 Dynabeads 
(Life Technologies), to which 4 μL of 1:100 dilution of the ERCC spike-in mix 1 (Ambion, 
Life technologies) was already added (Baker et al., 2005). There are a total of 92 
polyadenylated transcripts in this mix that are used to monitor sample and process 
consistency. mRNA is then fragmented by heat at 94°C for 15 minutes or less depending on 
sample RIN. First strand cDNA was synthesized using NEBNext RNA First Strand 
Synthesis Module (New England BioLabs) and during second strand cDNA synthesis, dNTP 
mix containing dUTP was used to introduce strand-specificity with NEBNext Ultra 
Directional RNA Second Strand Synthesis Module (New England BioLabs). For Illumina 
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paired-end library construction, the resultant cDNA is processed through end-repair and A-
tailing, ligated with Illumina PE adapters, and then digested with 10 units of Uracil-DNA 
Glycosylase (New England BioLabs). Libraries are prepared on the Beckman BioMek FXp 
robots and amplification of the libraries was performed for 13 PCR cycles using the Phusion 
High-Fidelity PCR Master Mix (New England BioLabs); 6-bp molecular barcodes that were 
also incorporated during this step. Libraries were purified with Agencourt AMPure XP 
beads (Beckman Coulter) after each enzymatic reaction, and after PCR amplification, and 
were quantified using Fragment Analyzer electrophoresis system. Libraries were pooled in 
equimolar amounts (4 libraries/pool). Library templates were prepared and sequenced 
exactly as described above for DNA Sequencing. Sequencing runs generated approximately 
300-400 million successful reads on each lane of a flow cell, yielding 75-100M reads per 
sample.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mouse Read Subtraction from WES Sequencing Data—Raw fastq files (n = 240) 
from Whole exome sequencing data were aligned to a combined hybrid genome of human 
hg19 and mouse mm10 genomes using the Burrows-Wheeler transformation algorithm 
(BWA v0.7.17-r1188). Reads overlapping specifically to either the human or mouse genome 
were extracted and separated in corresponding human and mouse bam files using Samtools 
v1.9. The mouse subtracted bam files containing reads specific to human genome were then 
sorted by name and only paired reads were kept using the Samtools parameter −f 1. 
Following this, duplicated reads were marked using Sambamba v0.6.6. The resulting bam 
files were then used as input for local realignment around indels using IndelRealigner and 
base quality score recalibration using BaseRecalibrator utilities from GATK v3.8.1.
Whole Exome Mutation Analysis—Many of these PDX models have been established 
decades ago, thus matched primary and/or normal tissue either were not collected or is not 
currently available. To filter common germline variation from these tumor models, we used a 
panel of 809 normal samples supplied from TCGA WBC tissue to generate consensus 
germline variant calls. Rare germline variation was retained and defined as < 0.005 minor 
allele frequency in any one of the three databases: Exome Aggregation Consortium (ExAC) 
(Lek et al., 2016), 1000 genomes, or the NHBLI Exome Sequencing Project (ESP). Filtered 
variants also present in COSMIC were scavenged back. We performed MutSigCV 
(Lawrence et al., 2013) analysis on the entire cohort to identify and remove false positive 
variants. With the exception of known oncogenes and tumor suppressors, novel significantly 
mutated genes (SMGs) common across all histologies should be rare. We manually 
inspected the top 100 SMGs and found that most novel genes harbored a high number of 
private mutations and thus were not removed. Other novel variants were false positives due 
to germline inclusion or sequencing/mapping errors (data on FigShare, link below). Data 
were thus split into germline MAF and somatic MAF files, the latter of which retained 
private variants.
Tumor Mutation Burden Analysis—Using the maftools R package (Mayakonda et al., 
2018), total number of mutations per variant type per model were calculated. We defined 
tumor mutation burden using only mononucleotide substitutions resulting in amino acid 
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changes: (Σ(somatic nonsynonymous + missense variants)/45.1 Mb). The denominator was 
the 45.1 Mb size of the Roche Nimblegen VCRome v. 2.1 capture panel.
ATRX Deletion Analysis—The ATRX locus on chromosome X contains too few probes 
in OmniExpress arrays to accurately assess deletion, even in cases of known sex. Thus, from 
WES bam files, total read base counts for ATRX exons were calculated using Samtools v1.9 
bedcov utility and total library size was calculated using Samtools v1.9 flagstat utility. To 
convert exon read counts to Fragments per kilobase per million reads (FPKM), the library 
sizes were first transformed to per million scaling factors. Following this, raw read counts of 
each exon were normalized using the per million scaling factors and the corresponding exon 
length.
Mutational Signatures Analysis—The deconstructSigs R package with the COSMIC 
30 signature reference was used. We ran this workflow on models with ≥ 50 total somatic 
mutations. We chose a cosine similarity value cutoff at 0.1 and plotted the proportion of 
signatures in each model as a stacked barplot.
Classifier Analysis—We applied models derived from three supervised machine learning 
algorithms to all PDX models with available RNA-Seq data (n = 244). The models were 
previously trained on RNaseq, copy number, and mutation data across 33 different adult 
cancer-types from The Cancer Genome Atlas PanCanAtlas project (Cancer Genome Atlas 
Research Network et al., 2013). Briefly, the algorithm was an elastic net penalized logistic 
regression classifier that took FPKM and z-score normalized RNaseq data as input and, in 
three independent classifiers, was trained to predict Ras pathway activation, NF1 
inactivation, and TP53 inactivation using mutation and copy number alteration status of 
corresponding samples. The Ras pathway and NF1 classifiers and the overall method were 
described in more detail in Way et al. (2018). The application and validation of the TP53 
classifier was described in Knijnenburg et al. (2018).
To assess performance of the TCGA trained classifiers applied to the PDX data, we used 
orthogonal evidence of gene alterations in each PDX sample. Specifically, we used samples 
with observed missense, nonsense, frameshift, and splice site mutations in ALK, BRAF, 
CIC, DMD, HRAS, KRAS, NF1, NRAS, PTPN11, and SOS1 as samples with possible Ras 
pathway activation. We used samples with only non-silent NF1 mutations for the NF1 
classifier, and samples with deleterious TP53 mutations, copy number deletions, and fusions 
for the TP53 classifier. We assessed model performance using receiver operating 
characteristic (ROC) and precision recall (PR) curves using these samples as the positive set 
and all others as the negative set. We also applied the classifiers to shuffled PDX gene 
expression matrices and compared performance to the real data to assess potential model 
bias. The reproducible analysis pipeline can be viewed at https://github.com/marislab/pdx-
classification and the software is archived on Zenodo at https://doi.org/10.5281/Zenodo.
1475249.
mRNA Gene Expression Analysis—Raw fastq files (n = 244) from RNA-sequencing 
data were aligned to a combined hybrid genome of human hg19 and mouse mm10 genomes 
using the STAR aligner v2.5.3a. Reads overlapping specifically to either the human or 
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mouse genome were extracted and separated in corresponding human and mouse bam files 
using Samtools v1.9. The mouse subtracted bam files containing reads specific to human 
genome were then sorted by name and only paired reads were kept using the Samtools 
parameter −f 1. Following this, duplicated reads were marked using Sambamba v0.6.6. The 
resulting bam files were used to extract and separate reads into paired-ended fastq files using 
the SamToFastq utility of Picard v2.18.14-0. The resulting paired-ended fastq files obtained 
after mouse subtraction were re-aligned to human genome hg19 using STAR aligner and 
marked for duplicate reads using Picard MarkDuplicates. Gene expression was quantified in 
terms of Fragments Per Kilobase of transcript per Million mapped reads (FPKM) using 
HTSeq v0.9.1 and Cufflinks v2.2.1. We also processed RNA-sequencing patient data from 
TARGET (ALL, n = 533; AML, n = 364; NBL, n = 169; RT, n = 70; OS, n = 87; WT, n = 
136) and PPTC PDX data (n = 244) using STAR alignment and RSEM normalization using 
hg38 as reference genome and Gencode v23 gene annotation to get transcript per million 
(TPM) expression values. For PPTC PDX data, human bam files generated from the mouse 
subtraction pipeline were used in order to generate input fastq files.
mRNA Variant Calling, Filtering, and Comparison to DNA Variants—Variant 
calling for RNA-seq samples was performed with Strelka v2.9.2 germline indels calling 
pipeline using hg19 primary assembly reference fasta and default parameters. VCFs were 
converted to MAF and variants were filtered for those that passed VEP and were non-silent 
(! = Silent or Intron). Variant allele frequencies for all non-silent, VEP-passed RNA variants 
were calculated. For each model on which both WES and RNA-Seq were performed, WES 
variants with RNA evidence were matched in the DNA MAF and VAF correlations were 
plotted and are stored in the QC folder of the FigShare project: https://figshare.com/projects/
Genomic_profiling_of_childhood_tumor_patient-
derived_xenograft_models_to_enable_rational_clinical_trial_design/38147.
Copy Number Analysis—SNP arrays were processed at the HGSC using the Illumina 
Infinium HTS Assay according to the manufacturer’s guidelines. Human OmniExpress 
arrays (Illumina, catalog No. WG-315-1101) were used, interrogating 741 thousand SNP 
loci with a MAF detection limit of 5%. SNP calls were collected using Illumina’s 
GenomeStudio software (version 1.0/2.0) in which standard SNP clustering and genotyping 
were performed with the default settings recommended by the manufacturer. Data from 
samples that met a minimum SNP call rate of 0.9 were considered passing and were 
included in subsequent analyses. Output files from Genome Studio containing BAF and 
LRR were used as input for Nexus 8.0. Quadratic systematic correction was performed using 
a custom file (Figshare repository, below) containing common snp probes from the two chip 
types. The significance threshold was reduced to 1 × 10−8 to reduce background noise. 
Segmentation was performed using Nexus’s SNPRANK algorithm. To extract segments, 
gain was set to 0 and loss to −1 × 10−11. The output table was reformatted to segmentation 
file format for input to GISTIC2.0, which was used to calculate broad and focal, hemizygous 
gene-level copy number events. Relevant arm and band level alterations were used in 
oncoprints. Since normal DNA was not available for paired analyses, sex chromosomes were 
removed. Focal homozygous deletions and amplifications were annotated using the 
segmentation file created post-Nexus analysis. A cutoff of LRR > = (0.538578182) was used 
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for amplifications and > = (−1.739) for deletions. Cutoffs were determined by assessing 
histogram splits for MYCN amplification, SMARCB1 deletion, and CDKN2A/B deletions. 
Homozygous deletions remained only if mRNA FPKM was < 5 or if RNA-Seq for a sample 
was not available. Manual inspections were performed to confirm alterations for 
SMARCB1, TP53, WT1, MYCN, C19MC, CDKN2A/B and edited when necessary (see 
code).
Breakpoint Analysis—We defined breakpoint regions as regions with 10% copy number 
change between adjacent segments. These were tabulated per autosome per model and 
plotted by histology in Figure S4C. To defined regions of high breakpoint density (HBD) as 
≥ 10 breakpoints per chromosome (Figure S4D; Table S3).
Ethnicity Inference—Approximate genomic ancestries for each PDX model were 
inferred through principal component analysis of SNP array genotypes. Illumina-designated 
plus-strand genotypes were exported from GenomeStudio and processed using PLINK 1.9. 
Sex chromosomes and SNPs with minor allele frequency < 1%, call rate < 90%, ora 
deviation from Hardy-Weinberg equilibrium surpassing p = 0.00005 were excluded. The 
PDX dataset was then merged with HapMap 3 (draft release 2), restricting to only the 
intersecting SNPs. This set was pruned to remove highly correlated SNPs using a window 
size of 50 variants, step size of 5 variants, and pairwise r2 threshold of 0.1. The 39,544 
remaining SNPs were used to calculate the top 20 principal components. Approximate 
ethnicities were inferred using the first two components. Individuals were classified into four 
broad population groups: European (including HapMap CEU and TSI population samples), 
African (ASW, LWK, MKK, and YRI), East Asian (CHB, CHD, and JPT), and South Asian 
or Hispanic (GIH and MXL).
Fusion Transcript Analysis—We used four different fusion callers: STAR-Fusion 
v1.1.0, FusionCatcher v0.99.7b, deFuse and SOAPFuseon RNA-sequencing data of the PDX 
models (n = 244). A total of 50,796 unique fusions were predicted with the following 
breakdown: STAR-Fusion (n = 9,496), FusionCatcher (n = 3,822), deFuse (n = 30,393), and 
SOAPFuse (n = 7,085). To reduce the number of false positives, we used two parallel 
approaches: first to keep all fusions predicted as in-frame and second to keep all fusions 
where the 5′ or 3′ gene fuses promiscuously with multiple partners within the same 
histology. To filter out unreliable predictions, we further filtered the in-frame fusions by 
keeping fusions that were recurrently predicted in two or more models within the sample 
histology or fusions that were supported by at least two fusion callers. We removed any 
fusions where expression of both genes in the gene pair was found to be < 1 TPM value 
across all models or it was not reported by the gene quantification algorithm. We then 
combined the lists from the two approaches discussed above and filtered out any fusions that 
were predicted in more than one histology. To remove spurious fusions, we filtered all 
fusions annotated as “read-through” as a result of fusions between adjacent or neighboring 
genes. We further removed fusions identified in non-cancer tissues and cells as per GTEx in 
order to remove chimeric RNA that is normally found in healthy tissue. Next, we scavenged 
and annotated fusions that have been identified as “driver” fusions in literature and fusions 
that were validated using cytogenetics. Finally, we annotated the gene fusion partners with 
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oncogenes from COSMIC, kinases from Kinase.com, and transcription factors from 
AnimalTFDB to identify any oncogenic potential and functional relevance.
RNA Expression Clustering and Pathway Analyses—The UCSC TumorMap 
analysis was used to visualize clusters of expression profiles across PDX histologies 
(Newton et al., 2017). The expression values were transformed into log2(TPM + 1) space. 
We removed genes where more than 80% of the samples had no measurable expression and 
we applied a variance filter to remove the 20% least varying genes. This generated a gene by 
sample matrix containing 28,482 genes and 244 PDX samples. The expression values and 
PDX annotations were uploaded to the TumorMap portal for analysis. A Bayesian 
hierarchical model was used to infer differences in expression across PDX histologies. We 
used a hierarchical modeling strategy to leverage similarities across related tissues and to 
improve inferences for histologies with small sample sizes (Ji and Liu, 2010). The 
hierarchical model was implemented using the Stan statistical programming language 
(Carpenter et al., 2017).
We inferred the biological function of histology-specific expression by ranking the 
expression differences for each histology and performing gene-set enrichment analysis 
(GSEA). GSEA was performed using the fgsea software (Sergushichev, 2016). Statistically 
significant enrichment was defined as having an adjusted p value less than 0.05 and a 
normalized enrichment score greater than 2.0. Statistically insignificant enrichment scores 
were set to zero for heatmap visualization. The normalized enrichment scores were 
visualized using the seaborn clustermap software for tissue database scores and R for 
Hallmark pathway scores.
Pediatric cBioPortal Data Processing—All processed data: RNA-sequencing 
expression values (FPKM and Z-score), RNA fusions, mutation calls in Mutation 
Annotation Format (MAF), segmentation, and focal copy number values were formatted 
using the current cBioPortal v1.2.2 file format documentation.
DATA AND CODE AVAILABILITY
Raw Data Availability—Mouse and human separated DNA and RNA BAM files have 
been deposited into dbGAP under accession number phs001437.v1.p1.
INTERMEDIATE PROCESSED DATA AVAILABILITY
Variant files, SNP array files, contamination assessment files: https://figshare.com/projects/
Genomic_landscape_of_childhood_cancer_patient-derived_xenograft_models/38147
Processed Data Availability—WES mutations, mRNA expression, RNA fusions, 
segmentation, and gene copy number has been deposited into the publicly-available pediatric 
cBioportal at: https://pedcbioportal.org/study?id=pptc#summary
Code Created or Modified for Analysis in This Paper Have Been Deposited in 
GitHub—PDX mouse subtraction: https://github.com/marislab/pdx-mouse-subtraction
NGSCheckmate analysis: https://github.com/d3b-center/ngs_checkmate_wf
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Correlation analyses: https://github.com/marislab/create-pptc-pdx-corplots
PDX pie chart (Figure 1): https://github.com/marislab/create-pptc-pdx-pie
Oncoprint generation (Figures 2 and 3): https://github.com/marislab/create-pptc-pdx-
oncoprints
Medulloblastoma classification (Figure 2): https://github.com/PichaiRaman/
MedulloClassifier
Tumor mutation burden (Figures 3 and S3): https://github.com/marislab/pptc-pdx-tmb
Gene classification (Figure 4): https://github.com/marislab/pdx-classification
Classifier analysis (Figures 4 and S5): https://github.com/marislab/pptc-pdx-classifier-
analysis
RNA clustering and heatmaps (Figure 5): https://github.com/marislab/pptc-pdx-RNA-Seq-
clustering
RNA fusion analysis (Figure 5): https://github.com/marislab/pptx-pdx-fusion-analysis
Ethnicity inference (Figure S2): https://github.com/marislab/pptc-pdx-ethnicity-inference
Mutational signatures (Figure S3): https://github.com/marislab/pptc-pdx-mut-sigs
Copy number, breakpoint, and SV (ATRX deletion) analysis (Figure S4): https://github.com/
marislab/pptc-pdx-copy-number-and-SVs
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Multiplatform analysis facilitates genomic resource of 261 pediatric cancer 
PDX models
• PPTC PDX models are reflective of high-risk and chemotherapy resistant 
disease
• Inferred TP53 pathway inactivation correlates with pediatric cancer copy 
number burden
• Pediatric cancer PDX models will be useful for drug development 
prioritization
Rokita et al. Page 31
Cell Rep. Author manuscript; available in PMC 2019 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Study and Sample Overview
(A and B) Diversity of the 261 childhood tumors collected (A) and demographics and 
genomic assays performed by histology (B). Assays performed were whole-exome 
sequencing (n = 240), whole transcriptome (n = 244), and SNP array copy number analysis 
(n = 252). Each genomic assay was performed once per biological tumor sample.
See Figure S1 for analysis pipelines, Table S1 for model metadata, and Table S2 for STR 
profiles.
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Figure 2. PDX Models Recapitulate the Mutational Landscape of Childhood Cancers
(A–C) Oncoprints of somatic alterations (homozygous deletions, amplifications, SNVs, and 
fusions) in hallmark driver genes for PDX models for which exome sequencing was 
performed (n = 240, top 20 genes per histology shown). Oncoprints are grouped by acute 
lymphoblastic leukemias (A), CNS and rhabdoid tumors (B) and extracranial solid tumors 
(C).
(A) From left to right are B cell precursor ALLs (n = 33), T cell ALLs (n = 25), Philadelphia 
chromosome positive (Ph+) ALLs (n = 3), mixed lineage leukemias (MLL, n = 10), early T 
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cell precursor (ETP) ALLs (n = 6), and Philadelphia chromosome-like (Ph-like) ALLs (n = 
19).
(B) From left to right are atypical teratoid rhabdoid tumors (ATRTs; n = 8), 
medulloblastomas (MBs; n = 8), astrocytomas (n = 7), non-MB/non-ATRT CNS embryonal 
tumors (n = 7), ependymomas (n = 5), and extracranial rhabdoid tumors (n = 4).
(C) From left to right are neuroblastomas (n = 35), osteosarcomas (n = 34), Wilms tumors (n 
= 13), Ewing sarcomas (n = 10), fusion negative rhabdomyosarcomas (n = 6), fusion positive 
rhabdomyosarcomas (n = 6), and rare solid tumors (n = 7). Clinical annotations for all 
models include histology, patient phase of therapy from which PDX was derived, and sex. 
CNS tumors were also annotated with molecular subtype. Hemizygous deletions in TP53 are 
annotated for osteosarcoma models, in CDKN2A for leukemia models, and in WT1 for 
Wilms tumor models. Focal homozygous deletions correspond to loss of expression (FPKM 
< 1) in models for which RNA was available. For fusions, only the 5′ partner is shown. 
Total mutations (log 10) per model are plotted above each oncoprint and colored by 
mutation type. Each genomic assay was performed once per biological tumor sample.
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Figure 3. Mutational Landscape of Models Derived from Tumors at Relapse
(A) For BCP-ALL, T-ALL, neuroblastoma, and osteosarcoma (histologies with N ≥ 6 
models and multiple phases of therapy), oncoprints comparing hallmark alterations in 
models derived from diagnosis tumors to models derived from relapse tumors.
(B) Tumor mutation burden (TMB) is significantly (or near significantly) higher in relapse 
models, compared to models established at diagnosis for all histologies collapsed (ndx = 151, 
nrel = 77, Wilcoxon p = 2.2e–5), BCP-ALL (ndx = 19, nrel = 14, Wilcoxon p = 0.051), 
neuroblastoma (ndx = 12, nrel = 23, Wilcoxon p = 0.016), and T-ALL (ndx =11, nrel = 8, 
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Wilcoxon p = 0.0081). There was no difference between osteosarcoma models established at 
diagnosis and relapse (ndx = 25, nrel = 6, Wilcoxon p = 0.42). For patients in which models 
were established at both diagnosis and relapse, there was a significant increase in mutational 
burden upon relapse (ndx = 12, nrel = 13, p = 0.0083). All n’s denote biological replicates.
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Figure 4. Expression and Mutational Signatures Classify Pediatric PDX Models for TP53 and 
NF1 Inactivation
(A) Only TP53 and NF1 classifiers performed well in our dataset (AUROCTP53 = 0.89, 
AUROCNF1 = 0.77, AUROCRas = 0.55). Solid lines represent real scores, and dotted lines 
represent shuffled scores. Forthe samples measured (n = 244), 60 had TP53 alterations 
(24.6%); 30 had KRAS, HRAS, or NRAS alterations (12.3%); and 11 had NF1 alterations 
(4.5%).
(B) TP53 scores are significantly higher (nWT = 120, nALT = 124, Wilcoxon p < 2.2 e–16) in 
models with genetic aberrations in TP53 (mean score = 0.790) compared to those without 
alterations (mean score = 0.419).
(C) Classifier scores are plotted based on the TP53 pathway gene alteration present (nWT = 
120, nTP53 = 72, nCDKN2A = 63, nMDM2 = 5, nGORAB = 1, nATM = 11, nATR = 7, nRB1 = 16, 
nCHEK1 = 2, nCHEK2 = 3) or variant classification (n = 244 total samples).
(D) TP53 classifier scores across all histologies broken down by TP53 pathway gene (n = 
240).
(E) In osteosarcoma models (n = 30), all scores, regardless of variant type or gene, were 
high and predicted pathway inactivation. Overall copy number burden (number of 
breakpoints calculated from SNP array data; STAR Methods) correlates significantly with 
TP53 classifier score (R = 0.51, p = 1.8e–17, n = 239). All n’s denote biological replicates.
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Figure 5. Expression Profiles of PDX Models Cluster by Histology and Contain Driver Fusions
(A) TumorMap rendition of PDX RNA-seq expression matrices by histology.
(B) Gene set enrichment analysis for Hallmark pathways for histologies with n ≥ 4 samples 
demonstrates histology-specific biologic processes significantly altered (adjusted p < 0.05 
and NES > 2.0, N = 221). Samples were grouped by prior before GSEA (nbone sarcoma = 10, 
nbrain = 58, nleukemia = 90, nneuroblastoma = 35, nosteosarcoma = 36, nrenal = 14, nsoft sarcoma = 
18).
(C and D) Venn diagram of RNA fusion overlap among four algorithms (C) and high-
confidence fusion totals (D) demonstrates a higher overall number of fusions in hematologic 
malignancies (boxplots are graphed as medians with box edges as first and third quartiles; 
detailed Ns in Table S3). n = 244 RNA samples used as input, and all n’s represent 
biological replicates.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
KAPA HiFi DNA Polymerase Kapa Biosystems KK2612
Agencourt AMPure XP beads Beckman Coulter A63882
SeqCap EZ HGSC VCRome Kit v 2.1 Roche 06266380001
TruSeq SBS kit v3 HS Illumina FC-401-3001
Oligo(dT)25 Dynabeads Life Technologies 61002
ERCC spike-in mix #1 Ambion, Life Technologies 4456740
NEBNext RNA First Strand Synthesis Module New England Biolabs E7525S
NEBNext Ultra Directional RNA Second Strand 
Synthesis Module
New England Biolabs E7550S
Uracil-DNA Glycosylase New England Biolabs M0280L
Phusion High-Fidelity PCR Master Mix New England Biolabs M0531L
Infinium OmniExpress-24 Kit Illumina WG-315-1101
GenePrint24 System for STR Typing Promega B1870
Investigator Quantiplex Kit QIAGEN 387018
PrimeTime Gene Expression 2x qPCR mix IDT 1055772
Deposited Data
WES human and mouse BAM files This paper dbGAP phs001437
RNA-Seq human and mouse BAM files This paper dbGAP phs001437
Intermediate files This paper https://figshare.com/projects/
Genomic_landscape_of_childhood_cancer_patient-
derived_xenograft_models/38147
Processed data – somatic mutations, gene 
expression, RNA fusions, segmentation files, focal 
copy number
This paper https://pedcbioportal.org/login.jsp#summary
Processed data – SNP array-associated analyses 
files, FPKM matrix, WES MAF files
This paper Figshare
HapMap 3 draft release 2 International HapMap 
project
ftp://ftp.ncbi.nlm.nih.gov/hapmap/genotypes/
latest_phaseIII_ncbi_b36/plink_format/
Experimental Models: Organisms/Strains
261 pediatric PDX models This paper Table S1
Oligonucleotides
Human PTGER2 qPCR FWD primer, 5′-
GCTGCTTCTCATTGTCTCGG-3′
IDT custom
Human PTGER2 qPCR REV primer, 5′-
GCCAGGAGAATGAGGTGGTC-3′
IDT custom
Human pTGER2 qPCR probe, 5′-FAM-
CAGTGTCATTCTCAACCTCATCCGCA-IOWA-
BLACK-3′
IDT custom
Mouse pTGER2 qPCR FWD primer, 5′-
ACATCAGCGTTATCCTCAACC-3′
IDT custom
Mouse pTGER2 qPCR REV primer, 5′-
GCTACTGCCAGACAATCCG-3′
IDT custom
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REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse pTGER2 qPCR probe, 5′-TXRED-
TCATTCGCATGCACCGTCGGA-IOWA-
BLACK-3′
IDT custom
Software and Algorithms
FusionCatcher 0.99.7b Nicorici et al., 2014 https://github.com/ndaniel/fusioncatcher
STAR-Fusion 1.1.0 Haas et al., 2017 https://github.com/STAR-Fusion
STAR 2.5.2b Dobin et al., 2013 https://github.com/alexdobin/STAR
RSEM 1.2.28 Li and Dewey, 2011 https://github.com/deweylab/RSEM
TumorMap 1.0 Newton et al., 2017 https://tumormap.ucsc.edu/
Stan 2.16.0 Carpenter et al., 2017 https://github.com/stan-dev/cmdstan
Fgsea 1.5.1 Sergushichev, 2016 https://bioconductor.org/packages/release/bioc/html/
fgsea.html
Pandas 0.23.0 McKinney, 2010 https://pandas.pydata.org/
R, various R Core Team http://www.R-project.org/
Python 3.6.5 Python Core Team https://www.python.org/
Jupyter 1.0.0 Kluyver et al., 2016 https://jupyter.org/index.html
Seaborn 0.8.1 Seaborn Core Team https://seaborn.pydata.org/
Maftools 2.0.15 Mayakonda et al., 2018 https://github.com/PoisonAlien/maftools
R 3.4.3 R Core Team http://www.R-project.org/
ComplexHeatmap 2.1.0 Gu et al., 2016 https://www.bioconductor.org/packages/3.7/bioc/html/
ComplexHeatmap.html
deconstructSigs 1.8.0 Rosenthal et al., 2016 https://github.com/raerose01/deconstructSigs
Nexus 8.0 Biodiscovery https://www.biodiscovery.com/
GISTIC 2.0.23 Mermel et al., 2011 https://www.broadinstitute.org/node/358411
MutSigCV 1.3.01 Lawrence et al., 2013 http://software.broadinstitute.org/cancer/software/
genepattern/modules/docs/MutSigCV
HGSC Mercury 3.2 Reid et al., 2014 https://www.hgsc.bcm.edu/software/mercury
BWA 0.7.17-r1188 Li and Durbin, 2010 http://bio-bwa.sourceforge.net/
GATK 3.8.1 McKenna et al., 2010 https://www.broadinstitute.org/gatk/
PLINK 1.9 Chang et al., 2015 https://www.cog-genomics.org/plink/1.9/
PLINK 1.07 Purcell et al., 2007 http://zzz.bwh.harvard.edu/plink/
Samtools 1.9 Li et al., 2009 http://samtools.sourceforge.net/
Sambamba 0.6.6 Tarasov et al., 2015 https://github.com/biod/sambamba
Picard 2.18.14-0 2018 https://github.com/broadinstitute/picard
Cufflinks 2.2.1 Trapnell et al., 2010 https://github.com/cole-trapnell-lab/cufflinks
RNA-SeQC 1.1.8 Deluca et al., 2012 https://github.com/broadinstitute/rnaseqc
AlignStats 0.3 BCM-HGSC https://github.com/jfarek/alignstats
SOAPFuse 1.26 Jia et al., 2013 https://sourceforge.net/projects/soapfuse/
HTSeq 0.9.1 Anders et al., 2015 https://github.com/simon-anders/htseq
Pindel 0.2.5b5 Ye et al., 2009 https://github.com/genome/pindel
deFuse 0.7.0 McPherson et al., 2011 https://github.com/amcpherson/defuse
Bamutil 1.0.14 Jun et al., 2015 https://github.com/statgen/bamUtil
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REAGENT or RESOURCE SOURCE IDENTIFIER
Trinity 2.5.1 Grabherr et al., 2011 https://github.com/trinityrnaseq/trinityrnaseq
Strelka 2.9.2 Kim et al., 2018b https://github.com/Illumina/strelka
NGSCheckmate 1.0 Lee et al., 2017 https://github.com/parklab/NGSCheckMate
Other
TARGET pediatric tumors RNA-sequencing 
dataset
The TARGET Consortium https://ocg.cancer.gov/programs/target/data-matrix
GTEx normal tissues RNA-sequencing dataset The GTEx Consortium. 
2013
http://www.gtexportal.org/home/index.html
Exome Aggregation Consortium 0.3.1 Lek et al., 2016 http://exac.broadinstitute.org/
The International Genome Sample Resource and 
1000 genomes project
Birney and Soranzo, 2015 https://www.internationalgenome.org/
NHBLI Exome Sequencing Project (ESP) Exome Variant Server, 
NHLBI GO Exome 
Sequencing Project (ESP), 
Seattle, WA (URL: http://
evs.gs.washington.edu/
EVS/) [date (month, year) 
accessed].
http://evs.gs.washington.edu/EVS/
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